Pursuant to Regulations 33, 42 & 43 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ajanta Pharma has informed that Board of Directors of Company at their meeting held on 31st October, 2018, has approved Unaudited Consolidated and Standalone Financial Results of the Company for the quarter and half year ended 30th September, 2018; Unaudited Standalone Financial Results of the Company for the quarter and half year ended 30th September, 2018; and Payment of interim dividend of Rs 9 (450%) per equity share on the face-value of Rs 2 per share for the Financial Year 2018-19.
The above information is a part of company’s filings submitted to BSE.
